# NCEL catalysts: NewcelX Ltd. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/ncel/catalysts

> NewcelX Ltd. (NCEL) has 1 upcoming catalyst. The next is the clusters trial start, 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for NCEL?

NewcelX Ltd. (NCEL) has 1 upcoming catalyst. The next is the clusters trial start, 2027. Press release filed with the SEC (EX-99): "For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom, the advancement and development of NCEL-101, the initiation and timing of IND-enabling studies, its manufacturing capabilities and scalability, and the timing and commencement of its planned Phase 1/2a clinical trial, including its plans to commence such trial in 2027." [Calendar and source filings](https://sec-api.dev/companies/ncel/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001213900-26-117274, https://www.sec.gov/Archives/edgar/data/1783036/000121390026117274/ea031144001ex99-1.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/companies/ncel/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | NewcelX Ltd. |
| Ticker | NCEL (Nasdaq) |
| SEC CIK | 1783036 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/ncel |

## Cash runway

Cash $2.2M as of 2025-12-31; quarterly burn $692K; about 9.5 months of runway at that rate (XBRL company facts, accession 0001213900-26-049307).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 27, 2022 | [NewcelX Ltd. topline data readout](https://sec-api.dev/companies/ncel/catalysts) | NCEL |  | completed, positive | "20-25 specialized centers across the U.S. and positive top-line results were announced on September 27, 2022." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1783036/000121390025044868/ea0241513-20f_nlspharma.htm)) |
| late 2024 | [AEX-41 topline data readout](https://sec-api.dev/pdufa/aex-41) | NCEL |  | scheduled | "Final top line results from the ongoing study are expected to be shared by the end of this year." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783036/000121390024107656/ea022202101ex99-1_nlspharma.htm)) |
| 2027 | [Clusters trial start](https://sec-api.dev/pdufa/clusters) | NCEL |  | scheduled | "For example, NewcelX is using forward-looking statements when it discusses the timing and completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds therefrom, the advancement and development of NCEL-101, the initiation and timing of IND-enabling studies, its manufacturing capabilities and scalability, and the timing and commencement of its planned Phase 1/2a clinical trial, including its plans to commence such trial in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783036/000121390026117274/ea031144001ex99-1.htm)) |

## Drugs

- [AEX-41](https://sec-api.dev/pdufa/aex-41): 
- [Clusters](https://sec-api.dev/pdufa/clusters): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/ncel/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NCEL catalysts: NewcelX Ltd. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/ncel/catalysts

```bibtex
@misc{secapidev_companies_ncel_catalysts_20261116,
  title        = {NCEL catalysts: NewcelX Ltd. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/ncel/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_ncel_catalysts_20261116","title":"NCEL catalysts: NewcelX Ltd. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/ncel/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
